86330001198000863300011980000001420720--06-302025Q1false10000000.0010002750000000.001862367686378950.464.240.000.000.560.464.800.0500P3YP20Y00.050.05P61D2.000.464.240.000.560.464.80P3YP3Y110001420720us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:PurchaseAndSaleAgreementMember2024-05-172024-05-170001420720us-gaap:CommonStockMember2024-07-012024-09-300001420720us-gaap:CommonStockMember2023-07-012023-09-300001420720ibio:RubrycTherapeuticsIncMemberus-gaap:SeriesAPreferredStockMemberibio:StockPurchaseAgreementMember2021-08-232021-08-230001420720us-gaap:CommonStockMember2023-11-292023-11-2900014207202023-11-292023-11-290001420720us-gaap:RetainedEarningsMember2024-09-300001420720us-gaap:AdditionalPaidInCapitalMember2024-09-300001420720us-gaap:RetainedEarningsMember2024-06-300001420720us-gaap:AdditionalPaidInCapitalMember2024-06-300001420720us-gaap:RetainedEarningsMember2023-09-300001420720us-gaap:AdditionalPaidInCapitalMember2023-09-300001420720us-gaap:RetainedEarningsMember2023-06-300001420720us-gaap:AdditionalPaidInCapitalMember2023-06-300001420720ibio:FirstInsuranceFundingMemberus-gaap:NotesPayableOtherPayablesMemberibio:InsurancePremiumFinancingAgreementMember2024-09-300001420720ibio:WoodforestNationalBankMemberus-gaap:NotesPayableToBanksMemberibio:CreditAgreementWithWoodforestNationalBankMember2024-09-300001420720us-gaap:CommonStockMember2024-09-300001420720us-gaap:CommonStockMember2024-06-300001420720us-gaap:CommonStockMember2023-09-300001420720us-gaap:CommonStockMember2023-06-300001420720ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:NotesPayableToBanksMemberibio:WoodforestSettlementAgreementMember2024-05-170001420720ibio:ChardanCapitalMarketsMemberibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-04-010001420720ibio:ChardanCapitalMarketsMemberibio:CommonStockAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-04-010001420720ibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-260001420720ibio:CommonStockAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-260001420720ibio:AllianceGlobalPartnersMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-070001420720srt:MinimumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:StockOptionIssuances2023PlanMember2024-07-012024-09-300001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:StockOptionIssuances2023PlanMember2024-07-012024-09-300001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member2024-07-012024-09-300001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2023-12-092023-12-090001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:StockOptionIssuances2023PlanMember2024-07-012024-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:StockOptionIssuanceEmploymentInducementGrantMember2024-07-012024-09-300001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2024-07-012024-09-300001420720us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMember2024-10-012024-11-120001420720us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001420720us-gaap:RestrictedStockUnitsRSUMemberibio:OmnibusEquityIncentivePlan2023Member2024-07-012024-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:StockOptionIssuances2023PlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-07-012024-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:StockOptionIssuances2023PlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-07-012024-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:StockOptionIssuanceEmploymentInducementGrantMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-07-012024-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:StockOptionIssuanceEmploymentInducementGrantMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-07-012024-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMemberibio:StockOptionIssuanceProfessionalServiceFeeGrantMember2024-07-012024-09-300001420720srt:MinimumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2024-07-012024-09-300001420720srt:MinimumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member2024-07-012024-09-300001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2024-07-012024-09-300001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member2024-07-012024-09-300001420720us-gaap:SecuredDebtMember2024-09-300001420720us-gaap:NotesPayableToBanksMember2024-07-012024-09-300001420720us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720ibio:AllianceGlobalPartnersMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember2022-12-062022-12-060001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember2024-07-012024-09-300001420720us-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-04-012024-04-010001420720us-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-07-012024-06-300001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember2023-07-012024-06-300001420720us-gaap:SegmentDiscontinuedOperationsMember2024-07-012024-09-300001420720ibio:LetterOfCreditSanDiegoLeaseMember2024-09-300001420720ibio:CompanyPurchasingCardMember2024-09-300001420720ibio:LetterOfCreditSanDiegoLeaseMember2024-06-300001420720ibio:CompanyPurchasingCardMember2024-06-300001420720us-gaap:SegmentDiscontinuedOperationsMember2024-07-012024-09-300001420720ibio:WoodforestNationalBankMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember2024-05-312024-05-3100014207202023-07-012024-06-300001420720srt:MinimumMember2024-09-300001420720srt:MaximumMember2024-09-300001420720us-gaap:OfficeEquipmentMember2024-09-300001420720us-gaap:MachineryAndEquipmentMember2024-09-300001420720us-gaap:BuildingAndBuildingImprovementsMember2024-09-300001420720us-gaap:OfficeEquipmentMember2024-06-300001420720us-gaap:MachineryAndEquipmentMember2024-06-300001420720us-gaap:BuildingAndBuildingImprovementsMember2024-06-300001420720ibio:SeveralInstitutionalAndOneAccreditedInvestorMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-10-012024-11-120001420720ibio:AllianceGlobalPartnersMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-07-012024-09-300001420720ibio:AllianceGlobalPartnersMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-07-012024-06-300001420720ibio:HcWainwrightAndCompanyLlcMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2022-07-012023-06-300001420720ibio:OtsukaPharmaceuticalCo.LtdMemberus-gaap:IntellectualPropertyMemberibio:AssetPurchasingAgreementMember2024-02-252024-02-250001420720ibio:CollegeStationInvestorsLlcMemberibio:PurchaseAndSaleGroundLeaseAgreementMember2021-11-012021-11-010001420720ibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720us-gaap:ConvertiblePreferredStockMember2024-09-300001420720us-gaap:ConvertiblePreferredStockMember2024-06-300001420720ibio:SanDiegoMemberus-gaap:LandAndBuildingMember2024-09-300001420720ibio:SanDiegoMemberus-gaap:LandAndBuildingMember2024-06-300001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2023-06-190001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2024-09-300001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2024-06-300001420720ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember2024-05-312024-05-310001420720ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:NotesPayableToBanksMemberibio:WoodforestSettlementAgreementMember2024-05-172024-05-170001420720ibio:ChardanCapitalMarketsMemberibio:SeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-04-012024-04-010001420720ibio:ChardanCapitalMarketsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-04-012024-04-010001420720ibio:SeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720ibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-072023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-070001420720ibio:HcWainwrightAndCompanyLlcMembersrt:MinimumMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:HcWainwrightAndCompanyLlcMembersrt:MaximumMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember2022-12-062022-12-060001420720ibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember2022-12-062022-12-060001420720ibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:WainwrightUnderwritingAgreementMember2022-12-062022-12-060001420720ibio:BryanCapitalMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2021-11-012021-11-010001420720us-gaap:RetainedEarningsMember2024-07-012024-09-300001420720us-gaap:RetainedEarningsMember2023-07-012023-09-300001420720ibio:PrincipalMember2024-09-300001420720ibio:InterestMember2024-09-300001420720ibio:AssetsOperatedUnderOperatingLeaseMember2024-07-012024-09-300001420720ibio:AssetsOperatedUnderFinancingLeaseMember2024-07-012024-09-300001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2024-07-012024-09-300001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2023-07-012023-09-300001420720ibio:FirstInsuranceFundingMemberus-gaap:NotesPayableOtherPayablesMemberibio:InsurancePremiumFinancingAgreementMember2024-07-012024-09-300001420720us-gaap:SecuredDebtMember2023-07-012023-09-300001420720ibio:SanDiegoMemberus-gaap:FinancialStandbyLetterOfCreditMemberus-gaap:LandAndBuildingMember2021-09-100001420720ibio:ThomasF.IsettFormerChiefExecutiveOfficerMemberibio:SeparationAgreementAndGeneralReleaseMember2022-10-012022-12-310001420720us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMember2023-07-012024-06-300001420720us-gaap:IntellectualPropertyMember2024-09-300001420720us-gaap:IntellectualPropertyMember2024-06-300001420720us-gaap:EquipmentMemberus-gaap:SegmentContinuingOperationsMember2024-07-012024-09-300001420720us-gaap:EquipmentMemberus-gaap:SegmentContinuingOperationsMember2023-07-012023-09-300001420720us-gaap:EquipmentMember2024-09-300001420720us-gaap:EquipmentMember2024-06-300001420720us-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMember2023-07-012023-09-300001420720ibio:ThomasF.IsettFormerChiefExecutiveOfficerMemberibio:SeparationAgreementAndGeneralReleaseMember2024-09-300001420720us-gaap:SegmentContinuingOperationsMember2024-07-012024-09-300001420720us-gaap:SegmentContinuingOperationsMember2023-07-012023-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMemberibio:StockOptionIssuanceProfessionalServiceFeeGrantMember2024-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:StockOptionIssuances2023PlanMember2024-09-300001420720us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberibio:StockOptionIssuanceEmploymentInducementGrantMember2024-09-300001420720us-gaap:RetirementPlanNameOtherMember2024-07-012024-09-300001420720us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:RetirementPlanNameOtherMember2023-07-012023-09-300001420720us-gaap:RetirementPlanNameOtherMember2023-07-012023-09-300001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember2024-09-300001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberibio:CreditAndSecurityAgreementMember2024-07-012024-09-300001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberibio:CreditAndSecurityAgreementMember2024-07-012024-09-300001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember2024-07-012024-09-300001420720us-gaap:SecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-07-012024-09-300001420720us-gaap:SecuredDebtMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2024-07-012024-09-300001420720us-gaap:SecuredDebtMember2024-07-012024-09-300001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember2024-01-162024-01-160001420720ibio:FirstInsuranceFundingMemberus-gaap:NotesPayableOtherPayablesMemberibio:InsurancePremiumFinancingAgreementMember2023-10-302023-10-300001420720us-gaap:SecuredDebtMember2022-10-122022-10-120001420720ibio:FirstInsuranceFundingMemberus-gaap:NotesPayableOtherPayablesMemberibio:InsurancePremiumFinancingAgreementMember2023-10-300001420720us-gaap:SecuredDebtMember2022-10-120001420720ibio:WoodforestNationalBankMemberus-gaap:NotesPayableToBanksMemberibio:CreditAgreementWithWoodforestNationalBankMember2021-11-010001420720ibio:WoodforestNationalBankMemberibio:CreditAgreementWithWoodforestNationalBankMember2021-11-010001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMemberus-gaap:PrimeRateMember2024-01-162024-01-160001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementEventOfDefaultMemberus-gaap:BaseRateMember2024-01-162024-01-160001420720us-gaap:ConvertiblePreferredStockMember2022-05-090001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember2024-06-300001420720us-gaap:CommonStockMember2024-09-300001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2024-09-300001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2024-09-300001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member2024-09-300001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2023Member2023-12-090001420720us-gaap:EmployeeStockOptionMemberibio:OmnibusEquityIncentivePlan2020Member2020-12-090001420720ibio:HcWainwrightAndCompanyLlcMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2024-09-300001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-070001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-040001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-040001420720ibio:ChardanCapitalMarketsMemberibio:SeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-09-300001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-09-300001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-09-300001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-06-300001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-06-300001420720ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-06-300001420720ibio:HcWainwrightAndCompanyLlcMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2024-06-300001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-06-300001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-06-300001420720ibio:WoodforestNationalBankMemberibio:PreFundedWarrantsMemberus-gaap:SegmentDiscontinuedOperationsMemberibio:ContractDevelopmentAndManufacturingOrganizationMemberibio:WoodforestSettlementAgreementMember2024-05-310001420720ibio:WoodforestNationalBankMemberus-gaap:NotesPayableToBanksMemberibio:WoodforestSettlementAgreementMember2024-05-170001420720ibio:ChardanCapitalMarketsMemberibio:SeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-04-010001420720ibio:ChardanCapitalMarketsMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2024-04-010001420720ibio:SeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-260001420720ibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-260001420720ibio:AllianceGlobalPartnersMemberibio:SeriesDWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:SeriesCWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-070001420720ibio:AllianceGlobalPartnersMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:WarrantAgreementsMember2023-12-070001420720ibio:HcWainwrightAndCompanyLlcMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-040001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-030001420720ibio:HcWainwrightAndCompanyLlcMemberibio:SeriesBWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-030001420720ibio:HcWainwrightAndCompanyLlcMemberibio:RepresentativeWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-030001420720ibio:HcWainwrightAndCompanyLlcMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-030001420720ibio:HcWainwrightAndCompanyLlcMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2023-08-030001420720ibio:BryanCapitalMemberibio:CommonStockWarrantsMemberus-gaap:CommonStockMemberibio:WarrantAgreementsMember2021-11-010001420720ibio:BryanCapitalMemberus-gaap:CommonStockMemberibio:WarrantAgreementWithBryanCapitalMember2021-11-0100014207202023-09-300001420720ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember2022-09-162022-09-160001420720ibio:RubrycTherapeuticsIncMemberibio:AcquiredIntangibleAssetsMemberibio:AssetPurchaseAgreementMember2022-09-192022-09-190001420720ibio:RubrycTherapeuticsIncMemberibio:AcquiredFixedAssetsMemberibio:AssetPurchaseAgreementMember2022-09-192022-09-190001420720ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember2022-09-192022-09-190001420720ibio:RubrycTherapeuticsIncMemberibio:AcquiredSeriesPreferredStockMemberibio:StockPurchaseAgreementMember2021-08-232021-08-230001420720ibio:RubrycTherapeuticsIncMemberibio:AcquiredPrepaidExpensesMemberibio:StockPurchaseAgreementMember2021-08-232021-08-230001420720ibio:RubrycTherapeuticsIncMemberibio:AcquiredIntangibleAssetsMemberibio:StockPurchaseAgreementMember2021-08-232021-08-230001420720ibio:RubrycTherapeuticsIncMemberibio:StockPurchaseAgreementMember2021-08-232021-08-230001420720ibio:SanDiegoMemberus-gaap:LandAndBuildingMember2021-09-100001420720us-gaap:WarrantMember2024-07-012024-09-300001420720us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001420720us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001420720us-gaap:WarrantMember2023-07-012023-09-300001420720us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001420720us-gaap:EmployeeStockOptionMember2023-07-012023-09-3000014207202023-07-012024-09-300001420720us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001420720us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001420720us-gaap:SegmentDiscontinuedOperationsMember2023-07-012023-09-300001420720us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001420720us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001420720us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001420720us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-3000014207202023-06-3000014207202024-06-300001420720ibio:BryanCapitalMemberus-gaap:CommonStockMemberibio:WarrantAgreementWithBryanCapitalMember2021-11-012021-11-010001420720ibio:HcWainwrightAndCompanyLlcMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720ibio:HcWainwrightAndCompanyLlcMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720us-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720us-gaap:PrivatePlacementMember2024-03-262024-03-260001420720ibio:LoebTermSolutionsLlcMemberus-gaap:MediumTermNotesMemberibio:CreditAndSecurityAgreementMember2024-01-160001420720ibio:OtsukaPharmaceuticalCo.LtdMemberus-gaap:IntellectualPropertyMemberibio:AssetPurchasingAgreementMember2024-02-250001420720ibio:HcWainwrightAndCompanyLlcMemberibio:RepresentativeWarrantsMemberus-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMemberibio:WainwrightUnderwritingAgreementMember2022-12-092022-12-090001420720srt:MaximumMemberibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-252024-03-250001420720us-gaap:CommonStockMember2023-11-2900014207202023-11-290001420720ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember2022-09-160001420720srt:MinimumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-08-112023-08-110001420720ibio:SeveralInstitutionalAndOneAccreditedInvestorMemberibio:PreFundedWarrantsMemberus-gaap:CommonStockMemberus-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-11-120001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2024-08-292024-08-290001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMemberibio:OmnibusEquityIncentivePlan2023Member2023-12-092023-12-090001420720srt:MaximumMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMemberibio:OmnibusEquityIncentivePlan2020Member2020-12-092020-12-090001420720ibio:AllianceGlobalPartnersMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2023-12-072023-12-0700014207202023-07-012023-09-300001420720ibio:ThomasF.IsettFormerChiefExecutiveOfficerMemberibio:SeparationAgreementAndGeneralReleaseMember2023-01-012023-01-010001420720ibio:SafiBiosolutionsIncMemberus-gaap:NotesReceivableMember2020-10-012020-10-010001420720ibio:RubrycTherapeuticsIncMemberibio:AssetPurchaseAgreementMember2021-07-012022-06-300001420720ibio:Year2025Member2024-09-3000014207202024-09-300001420720ibio:RubrycTherapeuticsIncMemberus-gaap:CommonStockMemberibio:AssetPurchaseAgreementMember2022-09-162022-09-160001420720ibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720srt:MinimumMemberibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720srt:MaximumMemberibio:PreFundedWarrantsAndSeriesEWarrantsMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseStockAndWarrantsAgreementMember2024-03-262024-03-260001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-08-112023-08-110001420720srt:MaximumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-08-112023-08-110001420720ibio:RubrycTherapeuticsIncMemberibio:CollaborationOptionAndLicenseAgreementMember2021-08-232021-08-230001420720ibio:SanDiegoMemberus-gaap:LandAndBuildingMember2021-09-102021-09-100001420720ibio:ChardanCapitalMarketsLlcAndCraigHallumCapitalMarketsLlcMemberibio:AtMarketOfferingsMemberibio:AtMarketIssuanceSalesAgreementMember2024-08-060001420720srt:MaximumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-08-110001420720us-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:LincolnParkStockPurchaseAgreementMember2023-08-110001420720srt:MaximumMemberus-gaap:CommonStockMemberibio:AtMarketOfferingsMemberibio:CantorFitzgeraldUnderwritingAgreementMember2020-11-250001420720us-gaap:PrivatePlacementMemberibio:SecuritiesPurchaseAgreementMember2024-09-3000014207202024-11-0100014207202024-07-012024-09-30xbrli:sharesiso4217:USDxbrli:pureibio:leaseiso4217:USDxbrli:sharesutr:sqft

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission File Number 001-35023

iBio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

 

26-2797813

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

 

11750 Sorrento Valley Road, Suite 200, San Diego, CA

 

92121

(Address of principal executive offices)

 

(Zip Code)

(979) 446-0027

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading symbol(s)

 

Name of each exchange on which registered

Common Stock

 

IBIO

 

NYSE American

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes    No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes    No

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated Filer 

 

 

 

Accelerated Filer 

Non-accelerated Filer  

Smaller reporting company  

 

 

 

 

 

 

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes    No 

Shares of Common Stock outstanding as of November 12, 2024: 9,149,470

Table of Contents

iBio, Inc.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

3

 

 

Item 1.

Financial Statements:

Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and June 30, 2024

3

Unaudited Condensed Consolidated Statements of Operations for the three months ended September 30, 2024 and 2023

4

Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three months ended September 30, 2024 and 2023

5

Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2024 and 2023

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

33

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

46

Item 4.

Controls and Procedures

46

 

 

 

PART II. OTHER INFORMATION

47

 

 

Item 1.

Legal Proceedings

47

Item 1A.

Risk Factors

47

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

49

Item 5.

Other Information

49

Item 6.

Exhibits

50

 

 

SIGNATURES

51

2

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1.   Condensed Consolidated Financial Statements (Unaudited).

iBio, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

September 30, 

June 30, 

2024

2024

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$

11,038

$

14,210

Promissory note receivable and accrued interest

713

Prepaid expenses and other current assets

 

667

 

749

Total Current Assets

 

11,705

 

15,672

 

 

Restricted cash

223

215

Promissory note receivable

1,101

1,081

Finance lease right-of-use assets, net of accumulated amortization

 

271

 

339

Operating lease right-of-use asset

2,317

2,401

Fixed assets, net of accumulated depreciation

 

3,511

 

3,632

Intangible assets, net of accumulated amortization

5,363

5,368

Security deposits

26

26

Total Assets

$

24,517

$

28,734

 

 

Liabilities and Stockholders' Equity

 

 

Current liabilities:

 

 

Accounts payable

$

855

$

358

Accrued expenses

 

1,077

 

2,028

Finance lease obligations - current portion

279

299

Operating lease obligation - current portion

449

436

Equipment financing payable - current portion

182

178

Term promissory note - current portion

227

218

Insurance premium financing payable

123

Contract liabilities

400

200

Total Current Liabilities

 

3,469

 

3,840

 

 

Finance lease obligations - net of current portion

53

Operating lease obligation - net of current portion

2,572

2,688

Equipment financing payable - net of current portion

16

63

Term promissory note - net of current portion

706

766

Total Liabilities

 

6,763

 

7,410

 

 

Stockholders' Equity

 

 

Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at September 30, 2024 and June 30, 2024; 0 shares issued and outstanding as of September 30, 2024 and June 30, 2024

 

 

Common stock - $0.001 par value; 275,000,000 shares authorized at September 30, 2024 and June 30, 2024; 8,637,895 and 8,623,676 shares issued and outstanding as of September 30, 2024 and June 30, 2024, respectively

 

9

9

Additional paid-in capital

 

335,581

335,162

Accumulated deficit

(317,836)

(313,847)

Total Stockholders’ Equity

 

17,754

 

21,324

Total Liabilities and Stockholders' Equity

$

24,517

$

28,734

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Table of Contents

iBio, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited; in thousands, except per share amounts)

    

Three Months Ended

September 30, 

    

2024

    

2023

Revenue

$

$

50

 

 

Operating expenses:

 

Research and development

 

1,305

1,606

General and administrative

 

2,801

3,547

Total operating expenses

 

4,106

 

5,153

 

 

Operating loss

 

(4,106)

 

(5,103)

 

 

Other income (expense):

 

 

Interest expense

(57)

(26)

Interest income

 

174

55

Total other income

 

117

 

29

 

 

Net loss from continuing operations

(3,989)

(5,074)

Loss from discontinued operations

(672)

 

 

Net loss

$

(3,989)

$

(5,746)

Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - continuing operations

$

(0.46)

$

(4.24)

Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - discontinued operations

$

$

(0.56)

Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - total

$

(0.46)

$

(4.80)

 

 

Weighted-average common shares outstanding - basic and diluted

 

8,633

 

1,198

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents

iBio, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited; in thousands)

Three Months Ended September 30, 2024

Additional

Common Stock

Paid-In

Accumulated

 

Shares

 

Amount

 

Capital

 

Deficit

 

Total

Balance as of July 1, 2024

8,624

$

9

$

335,162

$

(313,847)

$

21,324

Common stock issued for warrants exercised

2

*

4

4

Vesting of RSUs

12

*

Share-based compensation

415

415

Net loss

 

 

 

(3,989)

 

(3,989)

Balance as of September 30, 2024

8,638

$

9

$

335,581

$

(317,836)

$

17,754

* Represents amount less than 0.5 thousand.

Three Months Ended September 30, 2023

Additional

Common Stock

Paid-In

Accumulated

 

Shares

 

Amount

 

Capital

 

Deficit

 

Total

Balance as of July 1, 2023

1,015

$

1

$

304,320

$

(288,940)

$

15,381

Capital raise

363

*

2,809

2,809

Vesting of RSUs

4

*

Share-based compensation

  

  

  

  

  

765

  

  

  

  

765

Net loss

 

 

 

(5,746)

 

(5,746)

Balance as of September 30, 2023

  

1,382

  

$

1

  

$

307,894

  

$

(294,686)

  

$

13,209

* Represents amount less than 0.5 thousand.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

Table of Contents

iBio, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited; in thousands)

    

Three Months Ended

September 30, 

    

2024

    

2023

Cash flows from operating activities:

Consolidated net loss

$

(3,989)

$

(5,746)

Adjustments to reconcile consolidated net loss to net cash used in operating activities:

 

 

Share-based compensation

 

415

 

765

Amortization of intangible assets

 

5

 

5

Amortization of finance lease right-of-use assets

68

68

Amortization of operating lease right-of-use assets

85

80

Depreciation of fixed assets

 

120

 

165

Gain on sale of fixed assets

(50)

Accrued interest receivable on promissory note receivable

(19)

(22)

Amortization of deferred financing costs

90

Changes in operating assets and liabilities:

 

 

Prepaid expenses and other current assets

 

(41)

 

212

Accounts payable

 

497

 

62

Accrued expenses

 

(952)

 

(874)

Operating lease obligations

 

(104)

 

(95)

Contract liabilities

 

200

 

Net cash used in operating activities

 

(3,715)

 

(5,340)

 

 

Cash flows from investing activities:

 

 

Payment received for interest and principal on promissory note receivable

713

Purchases of fixed assets

 

50

Net cash provided by investing activities

 

713

 

50

 

 

Cash flows from financing activities:

 

 

Proceeds from sales of common stock

4

2,808

Subscription receivable

204

Payment of equipment financing loan

(43)

(38)

Payment of term promissory note

(51)

Payment of term note payable

(436)

Payment of finance lease obligation

 

(72)

(66)

Net cash (used in) provided by financing activities

 

(162)

 

2,472

 

 

Net decrease in cash, cash equivalents and restricted cash

 

(3,164)

 

(2,818)

Cash, cash equivalents and restricted cash - beginning

 

14,425

 

7,579

Cash, cash equivalents and restricted cash - end

$

11,261

$

4,761

Supplemental cash flow information:

 

 

Cash paid during the period for interest

$

57

$

200

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

Table of Contents

iBio, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1.   Nature of Business

iBio, Inc. (also referred to as "iBio", or the "Company") is a preclinical stage biotechnology company leveraging the power of Artificial Intelligence (AI) and Machine Learning (ML) for the development of hard-to-drug precision antibodies. The Company’s proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Since September 2022, iBio has focused on utilizing AI and ML to discover and design antibodies against hard-to-drug targets upon the acquisition of substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc") was consummated. This acquisition commenced the Company’s transition from a Contract Development and Manufacturing Organization (CDMO) to an AI-enabled biotech company.  iBio’s transition concluded in May 2024 upon the closing of the sale of the CDMO facility in Texas.  These strategic decisions the Company executed enable it to solely focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.  

One of the key features of iBio’s technology stack is the patented epitope-steering AI-engine. This advanced technology allows us to target specific regions of proteins with precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile.  Another integral part of iBio’s technology stack is the ML based antibody-optimizing StableHu™ technology. When coupled with the Company’s mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.

iBio also developed the EngageTx™ platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of the Company’s antibody products. By incorporating EngageTx into iBio’s own development initiatives, the Company’s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to its potential partners.

iBio’s technology stack also includes ShieldTx™, an antibody masking technology enabling the creation of conditionally activated antibodies. These masks keep antibodies inactive until they reach diseased tissue, where the masks are removed, and the antibodies are activated. This mechanism is thought to broaden the therapeutic window, potentially improving efficacy and safety of treatments. Conditionally activated antibodies are also believed to enable the use of drug combinations that are otherwise considered too toxic, and they open the door to pursuing targets which, due to their expression in multiple tissues, would otherwise raise safety concerns.

iBio’s scientific team, comprised of experienced AI/ML scientists and biopharmaceutical scientists, located side-by-side in its San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows the Company to efficiently create a preclinical portfolio and rapidly advance preclinical pipeline programs towards clinical development.

Artificial Intelligence in Antibody Discovery and Development

iBio is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company’s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.

Pre-Clinical Pipeline

iBio is currently in the process of building and advancing its preclinical pipeline by leveraging its technology stack focused on hard-to-drug targets and molecules offering differentiation in both obesity and cardiometabolic disease space, as well as immune-oncology. The Company’s current therapeutics being developed are all in preclinical development and it has not completed any clinical trials in humans for any therapeutic protein product candidate produced using iBio technology and there is a risk that the Company will be unsuccessful in developing or commercializing any product candidates. As the Company continues to leverage its technology stack and develop its existing immune-oncology pre-clinical pipeline, the Company also is seeking strategic partners with the capabilities to more rapidly advance these programs towards the clinic. iBio also continues to assess its options rights to license three of the four assets under the

7

Table of Contents

AstralBio collaboration to add obesity and cardiometabolic programs into its pre-clinical pipeline. Under this strategic collaboration with AstraBio, it affords iBio the opportunity to expand the Company’s pipeline and build a presence in the cardiometabolic disease space.Graphic

2.   Basis of Presentation

Interim Condensed Consolidated Financial Statements

The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim consolidated financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K/A for the prior year ended June 30, 2024, filed with the SEC on September 24, 2024 (the “Annual Report”), from which the accompanying condensed consolidated balance sheet dated June 30, 2024 was derived.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of September 30, 2024 and the results of its operations and its cash flows for the periods presented. The results of operations for the three months ended September 30, 2024 are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.

Going Concern

In accordance with ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.

The Company generated negative cash flows from operations of approximately $3.7 million for the three months ended September 30, 2024. Historically, the Company’s liquidity needs have been met by the sale of common shares, and the issuance of common shares through the exercise of warrants. As of September 30, 2024, iBio had total current assets of approximately $11.7 million, of which approximately $11.0 million was cash and cash equivalents. The Company incurred a net loss of approximately $3.9 million during the

8

Table of Contents

three months ending September 30, 2024. As of September 30, 2024, the Company has a loss from operations of $3.7 million which compares to the $5.3 million loss from operations it maintained as of September 30, 2023.

The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company's ability to continue as a going concern. Management’s current financing and business plans have not mitigated such substantial doubt about the Company’s ability to continue as a going concern for at least 12 months from the date of filing this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 (the “Quarterly Report”).

In an effort to mitigate the substantial doubt about continuing as a going concern and increase cash reserves, the Company has raised funds from time to time through equity offerings or other financing alternatives, reduced its workforce, entered into a collaboration agreement to discover and develop novel antibodies for obesity and other cardiometabolic diseases and sold certain intellectual property rights. Potential options being considered to further increase liquidity include focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from the capital markets, grant revenue or collaborations, or a combination thereof. However, the Company anticipates that its expenses will increase as it continues its research and development activities and conducts clinical trials.

On July 3, 2024, the Company entered into an At Market Issuance Sales Agreement (the “ATM Agreement”) with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC (collectively, the “Sales Agents”) providing for the issuance and sale by the Company of its common stock, par value $0.001 per share (the “Common Stock”), from time to time, through the Sales Agents, with certain limitations on the amount of Common Stock that may be offered and sold by the Company as set forth in the ATM Agreement (the “ATM”). Offers and sales of shares of Common Stock by the Company, if any, under the ATM Agreement, is subject to the effectiveness of the Company’s shelf registration statement on Form S-3, filed with the SEC on July 3, 2024 which became effective on August 6, 2024. The aggregate market value of the shares of Common Stock eligible for sale under the ATM prospectus supplement included in the Registration Statement is currently $7,350,000, which is based on the limitations of General Instruction I.B.6 of Form S-3. No Common Stock was sold under this agreement as of September 30, 2024.

The accompanying condensed consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern.

Reverse Stock Split

On November 27, 2023, the Company’s Board approved the implementation of a reverse stock split (the “2023 Reverse Split”) at a ratio of one-for-twenty (1:20) shares of the Company's Common Stock. The 2023 Reverse Split was effective as of November 29, 2023. All share and per share amounts of the Common Stock presented in this Quarterly Report have been retroactively adjusted to reflect the 2023 Reverse Split. See Note 15 – Stockholders’ Equity for more information.

3.   Discontinued Operations

On November 3, 2022, the Company announced it was seeking to divest its contract development and manufacturing organization (iBio CDMO) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company reduced its workforce and sold at public auction equipment and other tangible personal property located at the 130,000 square foot cGMP facility located in Bryan, Texas (the “Facility”).

On May 17, 2024, iBio CDMO entered into a purchase and sale agreement, dated as of May 17, 2024 (the “2024 Purchase and Sale Agreement”) with The Board of Regents of the Texas A&M University System (“The Board of Regents”) pursuant to which iBio CDMO agreed to terminate the Ground Lease Agreement (the “Ground Lease Agreement) with The Board of Regents, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015 (together with the Ground Lease Agreement, the “Ground Lease”), related to 21.401 acres in Brazos County, Texas (the “Land”) and completed the sale to The Board of Regents of: (i) the buildings, parking areas, improvements, and fixtures situated on the Land (the “Improvements”); (iii) all iBio CDMO’s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the “Personal Property”); (iii) all iBio CDMO’s rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the “Contracts”); and (iv) all iBio CDMO’s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the “Intangibles”; and together with the Ground Lease, Improvements and Personal Property, collectively, the “Property”). The purchase price was $8,500,000.

9

Table of Contents

In connection with the purchase of the Facility, iBio CDMO entered into a Credit Agreement, dated November 1, 2021 (the “Credit Agreement”), with Woodforest National Bank (“Woodforest”) pursuant to which Woodforest had provided iBio CDMO a $22,375,000 secured term loan (the “Term Loan”) to purchase the Facility, which Term Loan was evidenced by a Term Note (the “Term Note”).  On May 17, 2024, iBio CDMO, the Company and Woodforest entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) which provided that iBio CDMO would pay to Woodforest the proceeds of the sale of the Property under the 2024 Purchase and Sale Agreement when received, determine in consultation with Woodforest the remaining balance due under the Credit Agreement (the “Indebtedness Deficiency Amount”) and thereafter the Company issued to Woodforest a pre-funded warrant to purchase 1,560,570 shares of Common Stock(“Pre-Funded Warrant”).  (See Note 12 – Debt for more information.)

On May 31, 2024, in accordance with the terms of the Settlement Agreement in consideration of the payment in full of all Obligations (as such term is defined under the Credit Agreement) (a) iBio CDMO paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the 2024 Purchase and Sale Agreement, and (ii) approximately $915,000 from restricted cash which had previously been held by Woodforest, and (b) the Company issued a Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest. The Pre-Funded Warrant expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share.

Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (each as defined in the Credit Agreement) were terminated and Woodforest released the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and the Company and iBio CDMO released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024.

During the fiscal year ended June 30, 2024, the Company recorded an additional fixed asset impairment charge of $3.1 million, a loss on the sale of the Facility of approximately $4.8 million and a gain on the extinguishment of debt of approximately $0.8 million in discontinued operations. (See Note 5 – Financial Instruments, Note 10 – Fixed Assets and Note 12 – Debt for more information.)

The results of iBio CDMO's operations ceased in the fiscal year ended June 30, 2024 and were reported as discontinued operations for the year ended June 30, 2024. No assets or liabilities associated with the discontinued operations of the CDMO remained on the balance sheet as of June 30, 2024. The Company had chosen not to segregate the cash flows of iBio CDMO in the consolidated statement of cash flow for the year ended June 30, 2024 and accordingly, supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Consolidated Financial Statements refers to the Company's continuing operations.

The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations and comprehensive loss (in thousands):

Three Months Ended

September 30, 2023

Operating expenses:

General and administrative

364

Gain on sale of fixed assets

(50)

Total operating expenses

314

Other expenses:

Interest expense - term note payable

(358)

Total other expenses

(358)

Loss from discontinued operations

$

(672)

10

Table of Contents

The following table presents the supplemental disclosures related to discontinued operations for the condensed consolidated statements of cash flows (in thousands):

Three Months Ended

September 30, 2023

Amortization of finance lease right-of-use assets

$

2

Supplemental cash flow information:

Cash paid during the period for interest

174

4.   Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 4 of the Notes to Consolidated Financial Statements in the Annual Report on Form 10-K/A for the year ended June 30, 2024.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies, the valuation of the pre-funded warrants issued related to the extinguishment of the Term Loan and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

Accounts Receivable

Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and any other factors considered appropriate. Management’s policy is to write off accounts receivable against the allowance for credit losses when a balance is determined to be uncollectible. At September 30, 2024 and June 30, 2024, the Company determined that an allowance for credit losses was not needed. The Company had accounts receivable of $0 at June 30, 2023.

Subscription Receivable

The Company accounts for any subscription receivable as a current asset. Subscription receivables represent funds related to the sale of Common Stock in which the funds have not yet been delivered to the Company. The funds are generally held in escrow on behalf of the Company and are delivered within a few days.

Revenue Recognition

The Company accounts for its revenue recognition under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. A contract with a customer exists only when: (i) the parties to the contract have approved it and are committed to perform their respective obligations, (ii) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“performance obligations”), (iii) the Company can determine the transaction price for the goods or services to be transferred, (iv) the contract has commercial substance and (v) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. The Company recognizes revenue when it satisfies its performance obligations by transferring control of a promised good or service to the customer. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.

The Company analyzes its contracts to determine whether the elements can be separately identifiable and accounted for individually or as a bundle of goods or services. Allocation of revenue to individual elements that qualify for performance obligations is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.

11

Table of Contents

If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September 30, 2024 and June 30, 2024, the Company had no credit loss provisions.

The Company generates contract revenue under the following types of contracts:

Fixed-Fee

Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.

Revenue can be recognized either 1) over time or 2) at a point in time.

Collaborations/Partnerships

The Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Company’s rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner.  

The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, Collaborative Arrangements (“ASC 808”). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers (“ASC 606”).

Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs.

No revenue was recognized for the three months ended September 30, 2024. Revenue in the amount of $50,000 was recognized from a non-refundable upfront license fee for the three months ended September 30, 2023.

Contract Assets

A contract asset is an entity’s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.

Contract assets consist primarily of the cost of project contract work performed by third parties whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September 30, 2024 and June 30, 2024, contract assets were $0.

Contract Liabilities

A contract liability is an entity’s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer’s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.

Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September 30, 2024, June 30, 2024 and June 30, 2023 contract liabilities were $400,000, $200,000 and $0, respectively.

12

Table of Contents

Leases

The Company accounts for leases under the guidance of ASC 842, Leases (“ASC 842”). The standard established a right-of-use (“ROU”) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company’s balance sheet, resulting in an increase in noncurrent assets and both current and noncurrent liabilities.

In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component.

The lease liability and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company’s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company’s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgement. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.

An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September 30, 2024 and June 30, 2024 consisted of money market accounts. Restricted cash at September 30, 2024 includes a letter of credit obtained related to the San Diego operating lease (see Note 14 – Operating Lease Obligations) and a Company purchasing card. The Company’s bank requires an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $0.2 million and $0.2 million at September 30, 2024 and June 30, 2024, respectively.

The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):

September 30, 

June 30,

2024

2024

Cash and equivalents

$

11,038

$

14,210

Collateral held for letter of credit - San Diego lease

198

198

Collateral held for Company purchasing card

25

17

Total cash, cash equivalents and restricted cash

$

11,261

$

14,425

The collateral held for the letters of credit for the San Diego lease and the Company purchasing card are classified as long-term on the condensed consolidated balance sheets at Septembe 30, 2024 and June 30, 2024.

Research and Development

The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (“FASB”) ASC 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expense was reported in continuing operations for the three months ended September 30, 2024 and 2023. No research and development expense was reported in discontinued operations for the three months ended September 30, 2024 and 2023.  

13

Table of Contents

Right-of-Use Assets

Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 8 Finance Lease ROU Assets and Note 13 Finance Lease Obligations for additional information.

Fixed Assets

Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to 10 years.

The Company monitors fixed assets for impairment indicators throughout the year. When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. Changes in the Company’s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

See Note 10 – Fixed Assets for additional information.

Intangible Assets

Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.

The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over 20 years. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.

For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.

Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company’s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

See Note 11 – Intangible Assets for additional information.

Share-based Compensation

The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.

The impact that share-based payment awards will have on the Company’s results of operations is a function of the number of shares awarded, the trading price of the Company’s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company’s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.

Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company

14

Table of Contents

estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 17 Share-Based Compensation for additional information.

Concentrations of Credit Risk

Cash

The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent upon daily bank balances and the strength of the financial institution. The Company has not incurred any losses on these accounts. At September 30, 2024 and June 30, 2024, amounts in excess of insured limits were approximately $496,000 and $664,000, respectively.

Revenue

During the three months ended September 30, 2024, the Company reported no revenue from continuing operations and discontinued operations. During the three months ended September 30, 2023, the Company reported license revenue from one research collaborator in continuing operations and no revenue in discontinued operations.

Segment Reporting

The Company operates as one reportable segment, which is that of a preclinical stage biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies. In accordance with Accounting Standards Codification (“ASC”) 280, Segment Reporting (“Segment Reporting”), the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under Segment Reporting due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by Segment Reporting can be found in the accompanying consolidated financial statements.

Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Company’s condensed consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): “Improvements to Reportable Segment Disclosures” (“ASU 2023-07”) to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Company’s 2025 fiscal year annual reporting period, with early adoption permitted. The adoption of ASU 2023-07 did not have a significant impact on the Company’s condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

In October 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-06, “Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative” (“ASU 2023-06”). This ASU incorporates certain SEC disclosure requirements into the FASB ASC. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC Topics, allow users to more easily compare entities subject to the SEC’s existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the ASC with the SEC’s regulations. The ASU has an unusual effective date and transition requirements since it is contingent on future SEC rule setting. If the SEC fails to enact required changes by June 30, 2027, this ASU is not effective for any entities. Early adoption is not permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures” (“ASU 2023-09”) to enhance the transparency and decision-usefulness of income tax disclosures, particularly in the rate reconciliation table and disclosures about income

15

Table of Contents

taxes paid. This ASU applies to all entities subject to income taxes. This ASU will be effective for public companies for annual periods beginning after December 15, 2024. The Company does not expect the adoption of ASU 2023-09 will have a significant impact on its consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.

5.   Financial Instruments and Fair Value Measurement

The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and term promissory note payable in the Company’s condensed consolidated balance sheets approximated their fair values as of September 30, 2024 and June 30, 2024 due to their short-term nature. The carrying value of the promissory note receivable, equipment financing payable and finance lease obligations approximated fair value as of September 30, 2024 and June 30, 2024 as the interest rates related to the financial instruments approximated market.

The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of plan investments that fall under each category, and the valuation methodologies used to measure these investments at fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Quoted prices for similar assets and liabilities in active markets or inputs that are observable.
Level 3 – Inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

6. Significant Transactions

Otsuka

On February 25, 2024, the Company entered into the PD-1 Purchase Agreement with Otsuka pursuant to which the Company sold and assigned to Otsuka, and Otsuka purchased and assumed, all intellectual property rights directly related to the Company’s PD-1 Assets developed or held for development. The Company received an upfront payment of $1.0 million in cash at closing which is reported as a gain in the fiscal year ended June 30, 2024.  The Company will also be eligible to receive additional contingent cash payments totaling up to $52.5 million upon the achievement of certain pre-specified clinical development and commercial milestones. The Company will recognize the potential milestone payments at the earlier of when the contingent consideration is realized or is realizable.

Affiliates of Eastern Capital Limited

On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (“iBio CDMO”, and collectively with the Company, the “Purchaser”) entered into a series of agreements (the “Transaction”) with College Station Investors LLC (“College Station”), and Bryan Capital Investors LLC (“Bryan Capital” and, collectively with College Station, “Seller”), each affiliates of Eastern Capital Limited (“Eastern,” a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:

(i)acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility’s ground lease;
(ii)acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and
(iii)otherwise terminated all agreements between the Company and the affiliates of Eastern.

The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&M University System (“Texas A&M”) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the “Sublease”) until the consummation of the sale of the Facility.

The Purchase and Sale Agreement

On November 1, 2021, the Purchaser entered into a purchase and sale agreement (the “PSA”) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement that it entered into with Texas A&M (the “Landlord’’) related to the land at which the Facility is located together with all improvements pertaining thereto (the “Ground Lease Property”), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest

16

Table of Contents

to any tangible personal property owned by Seller and located on the Ground Lease Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Ground Lease Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Ground Lease Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the “Warrant”) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the land. The Ground Lease Agreement included various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.

As discussed above, iBio CDMO is being accounted for as a discontinued operation.  In the fiscal year ended June 30, 2024, the assets acquired were sold and the asset lease was terminated. These assets were classified as assets held for sale on the June 30, 2023 consolidated balance sheet.

The Credit Agreement

In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan to purchase the Facility (the “Term Loan”), which Term Loan was evidenced by a term note (the “Term Note”). The Term Loan was advanced in full on the closing date. See Note 12 – Debt for further information of the Term Loan.

The Warrant

As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 2,579 shares of the Common Stock at an exercise price of $665 per share. The Warrant expires on October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the total shares that can be exercised under the Warrant, 579 of such shares were valued at $217,255 to reflect the final payment of rent due under the Sublease.  The Warrant, as shown on the consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Ground Lease Property acquired.  See Note 15 – Stockholders’ Equity for additional information.

RubrYc

On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (“RubrYc”) described in more detail below:

Collaboration and License Agreement

The Company entered into a collaboration and licensing agreement (the “RTX-003 License Agreement”) with RubrYc to further develop RubrYc’s immune-oncology antibodies in its RTX-003 campaign.  Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fieldsRubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.

Collaboration, Option and License Agreement

The Company entered into an agreement with RubrYc (the “Collaboration, Option and License Agreement”) to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc’s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) ten (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.

17

Table of Contents

Stock Purchase Agreement

In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (“Stock Purchase Agreement”) with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc’s Series A-2 preferred stock (“Series A-2 Preferred”) for $7,500,000.

The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:

Preferred stock

$

1,760,000

Intangible assets

4,300,000

Prepaid expenses

1,440,000

$

7,500,000

On September 16, 2022, the Company entered an asset purchase agreement with RubrYc (the “Asset Purchase Agreement”) pursuant to which it acquired substantially all of the assets of RubrYc. The Company issued 5,117 shares of the Common Stock to RubrYc with an approximate market value of $1,000,000 (the “Closing Shares”). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company’s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Asset Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.

Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations and dismissed bankruptcy proceedings in June 2023. The Company recorded an impairment of the investment in the amount of $1,760,000 during the year ended June 30, 2022 which was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, during the year ended June 30, 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under research and development expense.

The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:

Intangible assets

$

1,228,000

Fixed assets

114,000

$

1,342,000

In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. See Note 8 – Finance Lease ROU Assets and Note 13 – Finance Lease Obligations.

Former CEO Departure

Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the “CEO”) and former Chairman of the Board, agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.

Separation Agreement and General Release

In connection with Mr. Isett’s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the “Agreement”).  Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and remained an employee of the Company until December 31, 2022, on which date his employment with the Company terminated. Following Mr. Isett’s termination of employment with the Company, pursuant to the Agreement, Mr. Isett receives the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his base salary in equal bi-monthly installments for twenty-four (24) months; (ii) an amount equal to a pro rata share of his target bonus for fiscal year 2023; (iii) an amount equal to the target bonus in equal bi-monthly installments for the twenty-four (24) month severance

18

Table of Contents

period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), the Company will pay the full cost of this benefit for up to eighteen (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the eighteen (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to six (6) times the monthly amount paid by the Company for the COBRA subsidy.  The Agreement includes a general release of claims by Mr. Isett. The Company accrued approximately $2.13 million to general and administrative expenses in the second quarter of fiscal year 2023. As of September 30, 2024, approximately $0.3 million is recorded in accrued expenses on the condensed consolidated balance sheets.

7.   Promissory Note Receivable

On June 19, 2023, the Company was issued a promissory note (the “Note”) with Safi Biosolutions, Inc. (“Safi”) in the principal amount of $1,500,000, which was issued in exchange for the convertible promissory note (the “Convertible Note”) issued to the Company by Safi on October 1, 2020. The Note has a maturity date of two (2) years from the date of issuance and can be extended by the mutual consent of the Company and Safi for two (2) additional one (1) year terms upon the payment of all accrued interest accrued through the date of such extension. In addition, the outstanding balance under the Note, or portions thereof, is due within a specified number of days after the receipt by Safi in a closing of specified financing milestones as more detailed in the Note. The Note bears interest at the rate of 5% per annum, which will increase to 7% for the first one (1) year extension and 9% for the second one (1) year extension. Upon the issuance of the Note, the Convertible Note, which bore interest at the rate of 5% per annum and had a maturity date of October 1, 2023, was voided.

On August 29, 2024, the Company received a payment from Safi of approximately $713,000 for all interest owed and approximately $419,000 for a partial payment on the outstanding principal on the Note.

For the three months ended September 30, 2024 and 2023, interest income amounted to $19,000 and $22,000, respectively. As of September 30, 2024 the Note balance and accrued interest, which have been classified as long term, totaled $1,101,000.  At June 30, 2024, $713,000 was reported in current assets and $1,081,000 classified as long term.

8.   Finance Lease ROU Assets

The Company assumed three equipment leases in September 2022 as part of the RubrYc asset acquisition (see Note 6 – Significant Transactions).

The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):

    

September 30, 

    

June 30, 

2024

2024

ROU - Equipment

$

814

$

814

Accumulated amortization

 

(543)

 

(475)

Net finance lease ROU assets

$

271

$

339

Amortization of finance lease ROU assets was approximately $68,000 and $68,000 for the three months ended September 30, 2024 and 2023, respectively.

9.   Operating Lease ROU Assets

San Diego, California

On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California (the “San Diego Lease”).  Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $3,603,000.  The net carrying amount of this ROU operating lease asset was $2,317,000 and $2,401,000 at September 30, 2024 and June 30, 2024, respectively. See Note 14 - Operating Lease Obligations for additional information.

Bryan, Texas

On November 1, 2021, iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. This lease was terminated on May 31, 2024.      

19

Table of Contents

10.   Fixed Assets

The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):

    

September 30, 

    

June 30, 

2024

2024

Building and improvements

$

695

$

695

Machinery and equipment

 

3,545

 

3,545

Office equipment and software

403

403

4,643

4,643

Accumulated depreciation

(1,132)

(1,011)

Net fixed assets

$

3,511

$

3,632

Depreciation expense reported in continuing operations was approximately $120,000 and $165,000 for the three months ended September 30, 2024 and 2023.

11.   Intangible Assets

On August 23, 2021, the Company entered into a series of agreements with RubrYc (see Note 6 – Significant Transactions) whereby the Company in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T-regulatory (Tregs) cells while enhancing T effector (Teffs) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. In addition, the Company also received preferred shares and an option for future collaboration licenses.

On September 16, 2022, the Company entered into an asset purchase agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate.

The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):

    

September 30, 

    

June 30, 

2024

2024

Intellectual property – gross carrying value

$

400

$

400

Intellectual property – accumulated amortization

 

(40)

 

(35)

Total definite lived intangible assets, net of accumulated amortization

360

365

Intellectual property – indefinite lived

5,003

5,003

Total net intangible assets

$

5,363

$

5,368

Amortization expense was approximately $5,000 for the three month periods ended September 30, 2024 and 2023.

See Note 4 - Summary of Significant Accounting Policies and Note 5 – Financial Instruments and Fair Value Measurement for more information.

12.   Debt

The Credit Agreement

In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 Term Loan to purchase the Facility, which Term Loan was evidenced by the Term Note (for a complete description of the Transaction please see Note 6 – Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bore interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest

20

Table of Contents

was payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provided that it may be prepaid by iBio CDMO at any time and provided for mandatory prepayment upon certain circumstances.

Throughout the term of the Term Loan, the Company and Woodforest entered into amendments which, among other things, amended the maturity date, interest rate and liquidity covenant. (Refer to the Company’s Annual Report for more information.)

On May 17, 2024, iBio CDMO, the Company and Woodforest entered into the Settlement Agreement which provided that iBio CDMO pay to Woodforest the proceeds of the sale of the Property under the 2024 Purchase and Sale Agreement when received, determine in consultation with Woodforest the Indebtedness Deficiency Amount and thereafter the Company issued to Woodforest upon receipt of NYSE American LLC approval a Pre-Funded Warrant that expires upon full exercise thereof and is exercisable at a nominal exercise price equal to $0.0001 per share for 1,560,570 shares of the Company’s common stock which equals the $4,499,124.88 Indebtedness Deficiency Amount divided by $2.883 (the greater of the book value or the market value of the Company’s common stock at the time the Settlement Agreement was executed). Pursuant to the Settlement Agreement, upon the closing of the sale of the Property under the Purchase and Sale Agreement, Woodforest would purchase the Pre-Funded Warrant in satisfaction of the Indebtedness Deficiency Amount, Woodforest would release the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to such date, and the Company and iBio CDMO will release Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to such date.

On May 31, 2024, in accordance with the terms of the Settlement Agreement entered into on May 17, 2024 with Woodforest in consideration of the payment in full of all Obligations (as such term is defined under the Credit Agreement) (a) iBio CDMO paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under the 2024 Purchase and Sale Agreement, and (ii) approximately $915,000 from restricted cash which had previously been held by Woodforest, and (b) the Company issued Pre-Funded Warrant to purchase 1,560,570 shares of its common stock to Woodforest exercisable at a nominal exercise price equal to $0.0001 per share.

Pursuant to the Settlement Agreement, the Credit Agreement, the Guaranty dated November 1, 2021 and the other Loan Documents (as defined in the Credit Agreement) were terminated and Woodforest released the Company and iBio CDMO from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024, and the Company and iBio CDMO released Woodforest and its related parties from any and all claims, debts, liabilities or causes of action it may have against them prior to May 31, 2024.

At September 30, 2024 and June 30, 2024, the balance of the Term Loan was $0.

Equipment Financing

On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an imputed interest rate of 10.62% and securitized by certain assets purchased for the San Diego research site. The financing is payable in monthly installments of $16,230 through October 2025. At September 30, 2024, the balance owed under the financing was $198,000. Interest incurred under the financing for the three months ended September 30, 2024 and 2023 totaled approximately $6,000 and $10,000, respectively.

Future minimum payments under the equipment financing obligation are due as follows (in thousands):

Fiscal period ending on September 30:

    

Principal

    

Interest

    

Total

2025

$

182

$

12

$

194

2026

 

16

 

 

16

 

  

 

  

 

  

Total minimum equipment financing payments

 

198

$

12

$

210

Less: current portion

 

(182)

 

  

 

  

Long-term portion of minimum equipment financing obligation

$

16

 

  

 

  

Credit and Security Agreement

On January 16, 2024, the Company entered into a credit and security agreement (the “Credit and Security Agreement”) with Loeb Term Solutions LLC, an Illinois limited liability company (“Lender”), for a term loan or equipment line of credit loan (the “Loan”) pursuant to which the Company issued to Lender a term promissory note in the principal amount of $1,071,572 (the “2024 Term Note”) bearing

21

Table of Contents

interest at the Prime Rate, as quoted in the Wall Street Journal plus 8.5% (the “Effective Rate”), for proceeds of $1,027,455 after payment of $42,863 to Lender as an origination fee, $1,173 for appraisal costs, and $75 for bank wire fees.

The 2024 Term Note provides for monthly payments of principal and interest based on a four-year amortization period, with a balloon payment of all principal, accrued interest and any other amounts due on the two year anniversary of the 2024 Term Note. The Credit and Security Agreement granted to Lender a security interest in substantially all of the Company’s assets other than any intellectual property related to any of the Company’s filed patents (the “Loeb Collateral”) to secure the Company’s obligations under the 2024 Term Note. The 2024 Term Note is subject to a prepayment fee of: 4% of the principal amount being prepaid if the 2024 Term Note is prepaid during the first 12 months from its issuance, and 3% of the principal amount being prepaid if the 2024 Term Note is prepaid during the second 12 months from its issuance date.  

The Credit and Security Agreement provides that the Company may request that Lender make further loan advances to the Company subject to certain conditions, including that the Company is not otherwise in default under the Credit and Security Agreement and its obligations and liabilities to Lender do not exceed a borrowing base equal to the lesser of: (a) eighty percent (80.0%) of the forced liquidation value of the Company’s Eligible Equipment as determined by Lender in its sole reasonable discretion, or (b) a monthly dollar amount. The Credit and Security Agreement defines “Eligible Equipment” as equipment that (a) is owned by the Company free of any title defect or any lien or interest of any person except the lien in favor of the Lender; (b) is located at locations permitted by the Credit and Security Agreement; (c) in the Lender’s reasonable opinion, is not obsolete, unsalable, damaged or unfit for further use; (d) is appraised by an appraiser satisfactory to the Lender; (e) complies with any representation or warranty with respect to equipment contained in the Credit and Security Agreement; and (f) is otherwise acceptable to the Lender in its reasonable discretion.

The Company’s obligations to Lender under the 2024 Term Note and Credit Security Agreement are further secured by an validity guarantee, dated January 16, 2024 (the “Validity Guarantee”), executed by Dr. Martin Brenner and Felipe Duran in their individual capacity (the “Indemnitors”) for the benefit of Lender. The Validity Guarantee provides that the Indemnitors will indemnify the Lender from any loss or damage, including any actual, consequential or incidental loss or damage, suffered by Lender as a result of, or arising out of, among other things, any willful or intentional misrepresentation or gross negligence by the Company in connection with the Loan and any acts of fraud, conversion, misappropriation or misapplication of funds or proceeds of any Loeb Collateral by the Company or the Indemnitors.

The Credit and Security Agreement contains customary events of default. If an event of default occurs, the 2024 Term Note provides that regardless of whether the Lender elects to accelerate the maturity of the 2024 Term Note, the entire principal remaining unpaid hereunder shall thereafter bear interest at the rate equal to the Effective Rate plus 6% per annum.

The financing is payable in monthly installments of $30,710 through December 2025 and a balloon payment of $652,060 in January 2026. At September 30, 2024, the balance owed under the financing was $933,000. Interest incurred under the financing for the three months ended September 30, 2024 totaled approximately $41,000.

Future minimum payments under the term promissory note obligation are due as follows (in thousands):

Fiscal period ending on September 30:

    

Principal

    

Interest

    

Total

2025

$

227

$

141

$

368

2026

 

706

 

38

 

744

 

  

 

  

 

  

Total minimum term promissory note payments

 

933

$

179

$

1,112

Less: current portion

 

(227)

 

  

 

  

Long-term portion of minimum term promissory note obligation

$

706

 

  

 

  

Insurance Premium Financing

On October 30, 2023, the Company entered into an insurance premium financing agreement with FIRST Insurance Funding, a division of Lake Forest Bank & Trust Company, N.A., whereby approximately $597,000 was borrowed over ten months at an imputed interest rate of 8.5%. The financing is payable in monthly installments of $62,095 through August 2024.  At September 30, 2024, the balance owed under the financing was $0. Interest incurred under the financing for the three months ended September 30, 2024 totaled approximately $1,000.

22

Table of Contents

13.   Finance Lease Obligations

Equipment

As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000 as part of the RubrYc Asset Purchase Agreement. The monthly rental for the three leases is approximately $27,000 per month and all three expire on August 1, 2025.

The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).